Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a...

|By:, SA News Editor

Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a lack of exclusivity for a generic version of Abbott's (ABT -0.6%) Prometrium, and a weaker than expected Vancomycin launch. The firm also cuts its price target to $14 from $15.